United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride 20 meq in 15 ml - potassium chloride is indicated for the treatment and prophylaxis of hypokalemia in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. potassium chloride is contraindicated in patients on potassium sparing diuretics pregnancy category c animal reproduction studies have not been conducted with potassium chloride. it is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity. the normal potassium ion content of human milk is about 13 meq per liter. since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk. the safety and effectiveness of potassium chloride have been demonstrated in children with diarrhea and malnutrition from birth to18 years. clinical studies of potassium chloride did not include s

Ireland - English - HPRA (Health Products Regulatory Authority)

hope pharmaceuticals ltd - sodium thiosulfate; sodium nitrite - solution for injection - 30/250 milligram(s)/millilitre - antidotes; thiosulfate; sodium nitrite

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - lidocaine hydrochloride monohydrate, quantity: 20 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - lignocaine is indicated for the production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication or following resuscitation from cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: povidone; colloidal anhydrous silica; hypromellose; magnesium stearate - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin modified release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 50 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 200 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 20 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - oxycodone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; sodium chloride; hydrochloric acid; sodium hydroxide; water for injections - the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.